Clinical Trial Update: Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety of elotuzumab given over ~60 minutes with lenalidomide and dexamethasone in newly diagnosed or relapsed/refractory multiple myelo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Elotuzumab (elotuzumab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2017-01-11